Veracyte (VCYT) Competitors $25.25 +1.66 (+7.04%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$25.18 -0.07 (-0.28%) As of 07/25/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VCYT vs. ADPT, BEAM, GH, TWST, TXG, OPCH, RDNT, BTSG, SHC, and SGRYShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Adaptive Biotechnologies (ADPT), Beam Therapeutics (BEAM), Guardant Health (GH), Twist Bioscience (TWST), 10x Genomics (TXG), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), and Surgery Partners (SGRY). These companies are all part of the "medical" sector. Veracyte vs. Its Competitors Adaptive Biotechnologies Beam Therapeutics Guardant Health Twist Bioscience 10x Genomics Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Adaptive Biotechnologies (NASDAQ:ADPT) and Veracyte (NASDAQ:VCYT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability. Is ADPT or VCYT more profitable? Veracyte has a net margin of 7.13% compared to Adaptive Biotechnologies' net margin of -74.84%. Veracyte's return on equity of 6.14% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-74.84% -62.79% -24.55% Veracyte 7.13%6.14%5.60% Which has more volatility and risk, ADPT or VCYT? Adaptive Biotechnologies has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Do insiders & institutionals hold more shares of ADPT or VCYT? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 1.4% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher valuation and earnings, ADPT or VCYT? Veracyte has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M9.13-$159.49M-$0.96-11.20Veracyte$445.76M4.44$24.14M$0.4161.59 Does the media refer more to ADPT or VCYT? In the previous week, Veracyte had 4 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 9 mentions for Veracyte and 5 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.28 beat Veracyte's score of 1.08 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ADPT or VCYT? Adaptive Biotechnologies currently has a consensus price target of $10.57, suggesting a potential downside of 1.66%. Veracyte has a consensus price target of $40.90, suggesting a potential upside of 61.98%. Given Veracyte's higher possible upside, analysts plainly believe Veracyte is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 SummaryVeracyte beats Adaptive Biotechnologies on 11 of the 16 factors compared between the two stocks. Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.85B$6.85B$5.69B$9.50BDividend YieldN/A1.27%4.58%4.01%P/E Ratio61.5925.4528.1020.05Price / Sales4.4464.09432.4490.07Price / Cash22.7520.5536.2258.56Price / Book1.664.758.665.87Net Income$24.14M$176.14M$3.25B$258.55M7 Day Performance7.40%2.92%4.23%3.74%1 Month Performance-5.82%3.23%10.52%11.75%1 Year Performance6.45%7.28%34.41%18.03% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte3.6864 of 5 stars$25.25+7.0%$40.90+62.0%+6.3%$1.85B$445.76M61.59790News CoveragePositive NewsAnalyst UpgradeGap UpHigh Trading VolumeADPTAdaptive Biotechnologies2.823 of 5 stars$10.31-0.8%$10.57+2.5%+148.3%$1.58B$178.96M0.00790Positive NewsBEAMBeam Therapeutics2.2634 of 5 stars$21.03+1.3%$48.75+131.8%-32.5%$2.09B$63.52M0.00510Analyst RevisionGHGuardant Health4.4699 of 5 stars$45.64-1.8%$54.45+19.3%+39.1%$5.76B$739.02M0.002,021News CoverageUpcoming EarningsAnalyst RevisionTWSTTwist Bioscience4.3619 of 5 stars$34.77-1.1%$50.40+45.0%-37.4%$2.08B$312.97M-10.70990News CoveragePositive NewsTXG10x Genomics4.1334 of 5 stars$11.54-5.0%$14.13+22.4%-29.2%$1.42B$610.78M-8.881,240News CoverageOPCHOption Care Health4.5403 of 5 stars$29.17-1.1%$35.50+21.7%-4.2%$4.83B$5.00B21.528,088Positive NewsUpcoming EarningsRDNTRadNet3.7605 of 5 stars$57.94+0.8%$69.60+20.1%-7.4%$4.31B$1.83B273.7611,021News CoveragePositive NewsBTSGBrightSpring Health Services1.8425 of 5 stars$19.71-1.2%$24.90+26.3%+69.8%$3.51B$11.27B32.1735,000News CoverageUpcoming EarningsAnalyst DowngradeSHCSotera Health3.073 of 5 stars$11.01-0.5%$16.00+45.3%-9.6%$3.14B$1.10B17.843,000News CoveragePositive NewsSGRYSurgery Partners2.9703 of 5 stars$22.36+0.2%$33.56+50.1%-30.9%$2.86B$3.11B37.2015,000 Related Companies and Tools Related Companies Adaptive Biotechnologies Competitors Beam Therapeutics Competitors Guardant Health Competitors Twist Bioscience Competitors 10x Genomics Competitors Option Care Health Competitors RadNet Competitors BrightSpring Health Services Competitors Sotera Health Competitors Surgery Partners Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCYT) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VCYT Stock Alerts